Stocky turns companies like Travere Therapeutics, Inc. into a fun, safe way to learn investing — a virtual portfolio, live scores & charts, and real analyst data, with no real money.
Try Stocky free →Avoid. TVTX scores 33.6 on Growth Compounder despite modest execution, while a 56.2× forward P/E leaves no margin of safety. Leadership alignment at 33.5 reflects misaligned incentives and dilution concerns, and the Vulnerable profile—likely driven by biotech trial risk and narrow revenue concentration—lacks offsetting moat strength. Valuation does not justify the structural and operational risks.
Every stock is scored across six proprietary dimensions built for retail investors who want Buffett-quality analysis without a Bloomberg subscription. Here's the actual snapshot for Travere Therapeutics, Inc.:
Quality + moat + leadership + valuation + sentiment fused into a single 0–100 number. When you see 26/100, you know instantly whether to dig deeper or skip.
Pricing power, switching costs, network effects, and 10-year ROIC data. Same framework Morningstar charges for — free inside Stocky.
Founder tenure, insider ownership, CEO pay reasonableness, long-term value creation. Six factors, one score — turns "trust the CEO" into evidence.
Customer concentration, supply chain, refinancing walls, regulatory exposure. Stocky maps knowable fragilities so you're never blindsided.
Every score backtested against real S&P 500 returns. See how "Elite" (90+ Verdict) picks have performed vs the index — no black boxes.
Analyst target shifts, insider buys, big moves — plus a monthly Portfolio Health Report telling you what's actually driving your returns.
Stocky rates Travere Therapeutics, Inc. (TVTX) at 26/100 — an Avoid — fundamentals or risks are too weak. The score fuses business quality, moat width, leadership alignment, valuation and analyst signal into a single number. Avoid. TVTX scores 33.6 on Growth Compounder despite modest execution, while a 56.2× forward P/E leaves no margin of safety. Leadership alignment at 33.5 reflects misaligned incentives and dilution concerns, and the Vulnerable profile—likel
TVTX's current Stocky Verdict is 26/100, placing it in the "Avoid" band. This composite combines a 34/100 Compounder score, 34/100 Leadership, Moat rating, and analyst signal.
Stocky hasn't finalised a Moat Score for Travere Therapeutics, Inc. yet — the analysis draws from ROIC trends, pricing power evidence, and competitive-position filings.
Travere Therapeutics, Inc. scores 34/100 on Leadership Alignment. Higher = more founder involvement, higher insider ownership, sensible pay, and evidence of long-term capital allocation discipline.
Travere Therapeutics, Inc.'s Vulnerability Profile scores 0/100 (higher = more resilient). The profile flags customer concentration, supply chain, refinancing walls and regulatory risks specific to Travere Therapeutics, Inc..
Sign up free and unlock the full analysis on TVTX — the same tools professional analysts use, personalised to your portfolio:
Free forever tier includes 5 Verdict lookups a day. Plus €19/mo unlocks everything above. Cancel any time.
This page is just a preview. Open the live, interactive version for the full picture:
Or jump straight to the interactive dashboard for TVTX in the app.
